AI PRICE FORECAST
AMGN Stock Forecast & AI Price Prediction
Amgen · Healthcare · Drug Manufacturers - General
AMGN live signal snapshot
Shares of AMGN were last at $468.11, up 0.62% on the day, trading 3.3% below its 52-week high of $483.99 and 49.8% above its 52-week low of $312.39. The model's verdict for AMGN right now: BUY (72% confidence). The short-term averages are tangled, giving no clean trend signal either way. Its one-month projection is about $484.14, a 3.4% move from the last price.
AMGN's 14-day RSI is 69.3 — healthy bullish momentum without being overextended. The MACD indicator is closing the gap to its signal line from below, so the downside momentum looks to be easing. The 50-day moving average ($424.39) sits 11.7% above the 200-day ($379.77) — a "golden cross" structure that typically supports the longer-term uptrend.
29 Wall Street analysts covering AMGN put the average price target at $431.81 (range $230.00–$536.00), implying 7.8% downside from the current price. The current recommendation trend leans bullish: 11 Buy/Strong Buy ratings vs 5 Sell/Strong Sell (and 18 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive AMGN dashboard for numbers updated throughout today's session.
About Amgen
Amgen Inc. (AMGN) is a drug manufacturers - general company in the healthcare sector, headquartered in Thousand Oaks, CA, United States. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It has a market value of about $253.2 billion and roughly 31,500 full-time employees. With a beta of 0.42, the stock has historically moved less than the overall market.
AMGN performance vs. the market
Year to date, AMGN has gained 43.0%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 44.6%, 33.1 points better than the S&P 500. Its +13.4% move over the past month extends a +12.0% three-month run.
| Period | AMGN | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +13.4% | +11.4% | −2.3% |
| 3 months | +12.0% | +12.2% | −2.3% |
| Year to date | +43.0% | +22.1% | +11.4% |
| 1 year | +44.6% | +28.3% | +11.5% |
Amgen financials at a glance
Amgen's most recent quarter (ended Sep 30, 2026) brought in $10.4 billion of revenue and net income of $3.9 billion (a 37.3% net margin). Revenue was up 8.5% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 27.1 on trailing earnings of $17.25 per share. Trailing free cash flow was $7.4 billion, and total debt equals 376% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $10.4B | $3.9B |
| Jun 30, 2026 | $10.1B | $2.4B |
| Mar 31, 2026 | $8.6B | $1.8B |
| Dec 31, 2025 | $9.9B | $1.3B |
AMGN vs. its peers
AMGN's +43.0% this year ranks ahead of 5 of the 5 big healthcare names below. None of them has done better this year.
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Amgen (AMGN) | $468.11 | +43.0% | 27.1 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
| Gilead Sciences (GILD) | $169.73 | +38.3% | — | BUY |
AMGN stock: common questions
What is the AMGN stock price target?
29 Wall Street analysts put the average 12-month target at $431.81, in a range of $230.00–$536.00, versus a recent price of $468.11. Stock Pulse 247's model projects about $484.14 over the next month.
Is AMGN a buy right now?
Our AI model currently rates AMGN a BUY at 72% confidence. Among analysts, 11 rate it Buy or Strong Buy, 18 Hold and 5 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has AMGN stock performed this year?
Year to date, AMGN has gained 43.0%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 44.6%, 33.1 points better than the S&P 500. Its +13.4% move over the past month extends a +12.0% three-month run.
What is AMGN's 52-week high and low?
AMGN has traded between $312.39 and $483.99 over the past 52 weeks; at $468.11 it is 3.3% below its 52-week high of $483.99 and 49.8% above its 52-week low of $312.39.
What sector is AMGN in, and who are its peers?
AMGN is in the healthcare sector (drug manufacturers - general). Its largest peers on Stock Pulse 247 include Eli Lilly and (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co. (MRK).
How accurate is the AMGN forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines AMGN's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.